Supplementary File S1

Treatment status of persons with MS receiving and not receiving B-cell depletion therapies (BCDT)

Treatment Status	**Discovery Cohort** (n)	**Validation Cohort** (n)
PwoMS	**16**	**24**
BCDT-treated PwMS	**7**	**28**
Anti-CD20 antibodies: Ofatumumab and ocrelizumab	5	28
Anti-CD52 antibody: Alemtuzumab	2	0
Non-BCDT-treated PwMS	**25**	**20**
Cladribine	2	2
Fingolimod	1	2
Dimethyl fumarate	3	2
Glatiramer acetate	9	6
Interferon-beta	1	1
Minocycline	2	1
Natalizumab	0	1
Teriflunomide	0	2
Non-treatment	7	3

Abbreviations: BCDT = B-cell depletion therapies; n = sample size